Results 41 to 50 of about 5,148 (157)

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report

BMC Pharmacology and Toxicology, 2020
Background Progressive bone pain and fracture and abnormal positron emission tomography combined with a computed tomography are main reasons for the oncologists suspecting bone tumor. During the patient’s medical treatment, the oncologists’ unfamiliarity
Qian Xiang, Zhiyan Liu, Yanyan Yu, Hanxu Zhang, Qiufen Xie, Guangyan Mu, Jianhua Zhang, Xinan Cen, Yimin Cui   +8 more
doaj   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, Volume 56, Issue 6, Page 903-913, June 2026.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real‐world associations between HBsAg loss and long‐term clinical outcomes in a diverse US population with chronic HBV infection. This
Myriam Drysdale, Rose Chang, Shuang Wang, Anna Coutinho, Vera Gielen, Theo Man, Rui Song, Mei Sheng Duh, Mandana Khalili, Dickens Theodore   +9 more
wiley   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang, Jia‐Lan Wang, Su‐Wen Jiang, Ai‐Wu Zhou, Meng‐Han Jin, Hao‐Jin Zhang, Shi‐Qi Yang, Shi‐Yang Fan, Ai‐Rong Hu   +8 more
wiley   +1 more source

Palliative Care Admission at End‐of‐Life in Liver Cancer: A 10 Year Population‐Based Study of 3565 Deaths in Australia

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Palliative care is essential to manage symptoms and end‐of‐life (EOL) quality, yet its utilisation in liver cancer remains poorly understood. This study examined sociodemographic and clinical characteristics associated with palliative care admission in the last 5 years of life for people with a death from liver cancer.
Rebecca J. Mitchell, Shenghan Cai, Jacob George, Rose Boutros, Amany Zekry, Yvonne Zurynski   +5 more
wiley   +1 more source

Entecavir interacts with influx transporters hOAT1, hCNT2, hCNT3, but not with hOCT2: the potential for renal transporter-mediated cytotoxicity and drug-drug interactions

Frontiers in Pharmacology, 2016
Entecavir (ETV) is one of the most potent agents for the treatment of the hepatitis B viral infection. The drug is principally eliminated by the kidney.
František eTrejtnar, Jana eMandíková, Marie eVolková, Petr ePávek, Lucie eNavrátilová, Lucie eHyršová, Zlatko eJaneba, Jan ePavlík, Pavel eBárta   +8 more
doaj   +1 more source

IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Pathogenic variants in IKZF1 (IKAROS) are linked to immunodeficiency, malignancy, and immune dysregulation. We describe a family with a rare IKZF1 variant presenting with humoral immunodeficiency and thrombotic thrombocytopenic purpura (TTP). A non‐consanguineous family was clinically monitored; clinical, immunological, and genetic data (exome
Ilia Spivak, Daniella Magen, Karin Weiss, Tamar Paperna, Suhair Hanna, Amos Etzioni, Adi Miller‐Barmak, Yonatan Butbul Aviel   +7 more
wiley   +1 more source

Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient

Gut and Liver, 2010
Adefovir dipivoxil (ADV) is commonly used as an antiviral agent in the treatment of chronic hepatitis B or human immunodeficiency virus infection. Nephrotoxicity has been shown to occur at daily dosages of 60-120 mg.
doaj   +1 more source